+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
GalNAc Delivery Technology Market - Global Forecast 2026-2032- Product Image
GalNAc Delivery Technology Market - Global Forecast 2026-2032- Product Image
Sale

GalNAc Delivery Technology Market - Global Forecast 2026-2032

  • Report

  • 193 Pages
  • September 2026
  • Region: Global
  • 360iResearch™
  • ID: 6121685
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The GalNAc Delivery Technology Market is projected to reach USD 599.21 Million in 2026. It is expected to continue growing at a CAGR of 7.39%, reaching USD 910.12 Million by 2032.

GalNAc Delivery Technology: Executive Overview

GalNAc delivery technology uses N-acetylgalactosamine ligands to direct therapeutic payloads toward asialoglycoprotein receptors, which are highly expressed on hepatocytes. This liver-targeting approach has become an important platform for nucleic-acid medicines, particularly small interfering RNA and related modalities. Its value proposition centers on selective delivery, subcutaneous administration, durable pharmacology, and the potential to reduce systemic exposure compared with less targeted approaches.

Targeted Delivery Is Reshaping Nucleic-Acid Medicine

The landscape is shifting from experimental delivery systems toward more defined, ligand-mediated platforms with established biological rationale and clinically validated use cases. Advances in conjugation chemistry, linker design, payload stabilization, manufacturing, and dose optimization are improving the practicality of GalNAc-based medicines. At the same time, developers must address receptor biology, tissue distribution, repeat-dose tolerability, immunogenicity, resistance mechanisms, and the limits of liver-selective delivery for diseases involving other organs.

Artificial Intelligence Accelerates Design, Selection, and Development

Artificial intelligence can support GalNAc programs by analyzing structure-activity relationships, prioritizing ligand and linker combinations, predicting physicochemical properties, and identifying potential safety liabilities earlier in development. Machine-learning tools can also help interpret pharmacokinetic, pharmacodynamic, transcriptomic, and clinical-response data to refine dose selection and patient stratification. These benefits depend on high-quality, standardized datasets and experimental validation; AI should therefore augment medicinal chemistry, toxicology, regulatory, and clinical expertise rather than replace it.

Regional Insights: Development Capacity and Regulatory Alignment Vary

North America combines advanced nucleic-acid research, specialized biotechnology infrastructure, and mature clinical-development capabilities. Europe benefits from strong academic networks and coordinated regulatory dialogue, while Asia-Pacific is expanding translational research, manufacturing capacity, and clinical expertise in RNA therapeutics. Latin America is more dependent on external innovation and access pathways, although selected markets offer growing clinical and pharmaceutical capabilities. The Middle East is developing biomedical and translational infrastructure unevenly, and Africa remains focused on strengthening research systems, specialist capacity, and access to advanced medicines. Across regions, regulatory clarity, analytical standards, local manufacturing, and reimbursement readiness will influence adoption.

Group Insights: Economic and Security Blocs Shape Collaboration

ASEAN offers a diverse set of healthcare systems and an opportunity for regional clinical and manufacturing partnerships, although regulatory harmonization remains uneven. BRICS countries provide substantial scientific, industrial, and patient-population capabilities but differ widely in regulatory practice and technology access. The European Union benefits from shared scientific and regulatory mechanisms, while the G7 combines deep research capacity with influential standards and financing ecosystems. GCC members are investing in healthcare modernization and strategic life-science capabilities. NATO countries collectively contribute significant biomedical infrastructure and translational research, although defense alignment does not create a uniform medicines policy. Cross-border partnerships should account for these institutional differences rather than treating each group as a single market.

Country Insights: Capabilities Range from Discovery to Manufacturing

The United States and Canada have strong discovery, clinical, and commercialization ecosystems. The United Kingdom, France, Germany, Italy, and Spain contribute established academic, pharmaceutical, regulatory, and clinical capabilities within a connected European environment. Japan and South Korea combine advanced biotechnology, precision-medicine research, and sophisticated manufacturing, while China is building substantial domestic capacity across RNA research and bioprocessing. India offers expanding pharmaceutical manufacturing and clinical-development expertise. Australia contributes high-quality biomedical research and clinical infrastructure. Brazil and Mexico are important Latin American centers for healthcare delivery, research, and regional access, while Russia retains scientific and industrial capabilities but operates within a complex international collaboration environment.

Prioritize Platform Discipline, Evidence Quality, and Access Planning

Industry leaders should define GalNAc programs around clear liver-targeted use cases and establish early decision criteria for tissue distribution, durability, repeat dosing, and safety. Investment should focus on scalable conjugation processes, robust analytical characterization, validated bioassays, and supply-chain resilience. Teams should integrate computational design with well-controlled experiments, maintain traceable datasets, and evaluate AI outputs for bias and reproducibility. Early engagement with regulators, clinicians, payers, and patient groups can clarify acceptable endpoints, administration preferences, monitoring requirements, and access barriers across regions. Partnerships should be selected for complementary capabilities in chemistry, payload biology, manufacturing, clinical development, and local regulatory execution.

Research Methodology: Evidence-Led Technology Assessment

This executive summary applies a qualitative assessment of GalNAc delivery technology using established principles of targeted drug delivery, nucleic-acid pharmacology, clinical development, manufacturing, and healthcare-system analysis. The review distinguishes documented platform characteristics from forward-looking implications and avoids unsupported estimates. Regional, group, and country observations are framed around research capacity, regulatory conditions, manufacturing maturity, clinical infrastructure, and access considerations. Because capabilities and policies change over time, conclusions should be updated against current peer-reviewed literature, regulatory publications, clinical-trial records, and validated technical disclosures before investment or portfolio decisions.

Conclusion: GalNAc Remains a Focused Platform with Broader Strategic Relevance

GalNAc delivery technology has established a compelling route for selective hepatocyte targeting and continues to influence the development of durable nucleic-acid medicines. Its strongest opportunities are linked to disciplined platform engineering, reliable translational evidence, scalable manufacturing, and careful selection of liver-mediated disease settings. Progress will depend not only on molecular innovation but also on regulatory alignment, data quality, regional partnerships, and equitable access. Leaders that combine technical rigor with practical development and implementation planning will be best positioned to translate GalNAc capabilities into durable clinical value.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. New Revenue Opportunities
3.4. Next-Generation Business Models
3.5. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. GalNAc Delivery Technology Market, by Therapeutic Area
7.1. Introduction
7.2. Cardiovascular Diseases
7.2.1. Atherosclerosis
7.2.2. Dyslipidemia
7.3. Liver Diseases
7.3.1. Hepatitis B
7.3.2. Non Alcoholic Steatohepatitis
7.4. Metabolic Disorders
7.4.1. Familial Hypercholesterolemia
7.4.2. Primary Hyperoxaluria
7.5. Oncology
8. GalNAc Delivery Technology Market, by Clinical Stage
8.1. Introduction
8.2. Commercial
8.3. Phase I/II
8.3.1. Phase I
8.3.2. Phase II
8.4. Phase III
8.5. Preclinical
9. GalNAc Delivery Technology Market, by Mechanism Of Action
9.1. Introduction
9.2. Antisense Oligonucleotides
9.2.1. Morpholino
9.2.2. Phosphorothioate
9.3. Gene Editing
9.3.1. Crispr Cas9
9.3.2. Talen
9.4. Mrna Therapies
9.4.1. Therapeutic Mrna
9.4.2. Vaccine Mrna
9.5. Rna Interference
9.5.1. ShRNA
9.5.2. SiRNA
10. GalNAc Delivery Technology Market, by End User
10.1. Introduction
10.2. Academic Institutions
10.3. Biotechnology Firms
10.4. Contract Research Organizations
10.5. Pharmaceutical Companies
11. GalNAc Delivery Technology Market, by Region
11.1. Introduction
11.2. Asia-Pacific
11.3. North America
11.4. Latin America
11.5. Europe
11.6. Middle East
11.7. Africa
12. GalNAc Delivery Technology Market, by Group
12.1. Introduction
12.2. ASEAN
12.3. GCC
12.4. European Union
12.5. BRICS
12.6. G7
12.7. NATO
13. GalNAc Delivery Technology Market, by Country
13.1. Introduction
13.2. United States
13.3. Canada
13.4. Mexico
13.5. Brazil
13.6. United Kingdom
13.7. Germany
13.8. France
13.9. Russia
13.10. Italy
13.11. Spain
13.12. China
13.13. India
13.14. Japan
13.15. Australia
13.16. South Korea
14. Competitive Landscape
14.1. Market Share Analysis, 2025
14.2. Market Concentration Analysis, 2025
14.2.1. Concentration Ratio (CR)
14.2.2. Herfindahl Hirschman Index (HHI)
14.3. Recent Developments & Impact Analysis, 2025
14.4. Product Portfolio Analysis, 2025
14.5. Benchmarking Analysis, 2025
15. Company Profiles
15.1. Akcea Therapeutics, Inc.
15.2. Alnylam Pharmaceuticals, Inc.
15.3. Arcturus Therapeutics Holdings Inc.
15.4. Arrowhead Pharmaceuticals, Inc.
15.5. AstraZeneca plc
15.6. Bayer AG
15.7. Beam Therapeutics Inc.
15.8. BioNTech SE
15.9. CRISPR Therapeutics AG
15.10. CureVac N.V.
15.11. Editas Medicine, Inc.
15.12. GlaxoSmithKline plc
15.13. Ionis Pharmaceuticals, Inc.
15.14. Moderna, Inc.
15.15. Novartis AG
15.16. Pfizer Inc.
15.17. Pfizer Inc.
15.18. Regeneron Pharmaceuticals, Inc.
15.19. Roche Holding AG
15.20. Sanofi S.A.
15.21. Sarepta Therapeutics, Inc.
15.22. Takeda Development Center Americas, Inc.
15.23. Takeda Pharmaceutical Company Limited
16. Key Experts
LIST OF FIGURES
FIGURE 1. Global GalNAc Delivery Technology Market, Years Considered for the Study
FIGURE 2. Global GalNAc Delivery Technology Market, Research Design
FIGURE 3. Global GalNAc Delivery Technology Market, Research Framework
FIGURE 4. Global GalNAc Delivery Technology Market, Data Triangulation
FIGURE 5. Global GalNAc Delivery Technology Market Size, 2017-2032 (USD Million)
FIGURE 6. Global GalNAc Delivery Technology Market Size, by Therapeutic Area, 2025 vs 2032 (%)
FIGURE 7. Global GalNAc Delivery Technology Market Size, by Therapeutic Area, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 8. Global GalNAc Delivery Technology Market Size, by Clinical Stage, 2025 vs 2032 (%)
FIGURE 9. Global GalNAc Delivery Technology Market Size, by Clinical Stage, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 10. Global GalNAc Delivery Technology Market Size, by Mechanism Of Action, 2025 vs 2032 (%)
FIGURE 11. Global GalNAc Delivery Technology Market Size, by Mechanism Of Action, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 12. Global GalNAc Delivery Technology Market Size, by End User, 2025 vs 2032 (%)
FIGURE 13. Global GalNAc Delivery Technology Market Size, by End User, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 14. Global GalNAc Delivery Technology Market Size, by Region, 2025 vs 2032 (%)
FIGURE 15. Global GalNAc Delivery Technology Market Size, by Region, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 16. Global GalNAc Delivery Technology Market Size, by Group, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 17. Global GalNAc Delivery Technology Market Size, by Country, 2025 vs 2032 (%)
FIGURE 18. Global GalNAc Delivery Technology Market Size, by Country, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 19. Global GalNAc Delivery Technology Market Share, by Key Player, 2025
LIST OF TABLES
TABLE 1. Global GalNAc Delivery Technology Market Segmentation & Coverage
TABLE 2. Global GalNAc Delivery Technology Market Size, 2017-2032 (USD Million)
TABLE 3. Global GalNAc Delivery Technology Market Size, by Therapeutic Area, 2017-2032 (USD Million)
TABLE 4. Global Cardiovascular Diseases Market Size, by Region, 2017-2032 (USD Million)
TABLE 5. Global Cardiovascular Diseases Market Size, by Group, 2017-2032 (USD Million)
TABLE 6. Global Cardiovascular Diseases Market Size, by Country, 2017-2032 (USD Million)
TABLE 7. Global Atherosclerosis Market Size, by Region, 2017-2032 (USD Million)
TABLE 8. Global Atherosclerosis Market Size, by Group, 2017-2032 (USD Million)
TABLE 9. Global Atherosclerosis Market Size, by Country, 2017-2032 (USD Million)
TABLE 10. Global Dyslipidemia Market Size, by Region, 2017-2032 (USD Million)
TABLE 11. Global Dyslipidemia Market Size, by Group, 2017-2032 (USD Million)
TABLE 12. Global Dyslipidemia Market Size, by Country, 2017-2032 (USD Million)
TABLE 13. Global Liver Diseases Market Size, by Region, 2017-2032 (USD Million)
TABLE 14. Global Liver Diseases Market Size, by Group, 2017-2032 (USD Million)
TABLE 15. Global Liver Diseases Market Size, by Country, 2017-2032 (USD Million)
TABLE 16. Global Hepatitis B Market Size, by Region, 2017-2032 (USD Million)
TABLE 17. Global Hepatitis B Market Size, by Group, 2017-2032 (USD Million)
TABLE 18. Global Hepatitis B Market Size, by Country, 2017-2032 (USD Million)
TABLE 19. Global Non Alcoholic Steatohepatitis Market Size, by Region, 2017-2032 (USD Million)
TABLE 20. Global Non Alcoholic Steatohepatitis Market Size, by Group, 2017-2032 (USD Million)
TABLE 21. Global Non Alcoholic Steatohepatitis Market Size, by Country, 2017-2032 (USD Million)
TABLE 22. Global Metabolic Disorders Market Size, by Region, 2017-2032 (USD Million)
TABLE 23. Global Metabolic Disorders Market Size, by Group, 2017-2032 (USD Million)
TABLE 24. Global Metabolic Disorders Market Size, by Country, 2017-2032 (USD Million)
TABLE 25. Global Familial Hypercholesterolemia Market Size, by Region, 2017-2032 (USD Million)
TABLE 26. Global Familial Hypercholesterolemia Market Size, by Group, 2017-2032 (USD Million)
TABLE 27. Global Familial Hypercholesterolemia Market Size, by Country, 2017-2032 (USD Million)
TABLE 28. Global Primary Hyperoxaluria Market Size, by Region, 2017-2032 (USD Million)
TABLE 29. Global Primary Hyperoxaluria Market Size, by Group, 2017-2032 (USD Million)
TABLE 30. Global Primary Hyperoxaluria Market Size, by Country, 2017-2032 (USD Million)
TABLE 31. Global Oncology Market Size, by Region, 2017-2032 (USD Million)
TABLE 32. Global Oncology Market Size, by Group, 2017-2032 (USD Million)
TABLE 33. Global Oncology Market Size, by Country, 2017-2032 (USD Million)
TABLE 34. Global GalNAc Delivery Technology Market Size, by Clinical Stage, 2017-2032 (USD Million)
TABLE 35. Global Commercial Market Size, by Region, 2017-2032 (USD Million)
TABLE 36. Global Commercial Market Size, by Group, 2017-2032 (USD Million)
TABLE 37. Global Commercial Market Size, by Country, 2017-2032 (USD Million)
TABLE 38. Global Phase I/II Market Size, by Region, 2017-2032 (USD Million)
TABLE 39. Global Phase I/II Market Size, by Group, 2017-2032 (USD Million)
TABLE 40. Global Phase I/II Market Size, by Country, 2017-2032 (USD Million)
TABLE 41. Global Phase I Market Size, by Region, 2017-2032 (USD Million)
TABLE 42. Global Phase I Market Size, by Group, 2017-2032 (USD Million)
TABLE 43. Global Phase I Market Size, by Country, 2017-2032 (USD Million)
TABLE 44. Global Phase II Market Size, by Region, 2017-2032 (USD Million)
TABLE 45. Global Phase II Market Size, by Group, 2017-2032 (USD Million)
TABLE 46. Global Phase II Market Size, by Country, 2017-2032 (USD Million)
TABLE 47. Global Phase III Market Size, by Region, 2017-2032 (USD Million)
TABLE 48. Global Phase III Market Size, by Group, 2017-2032 (USD Million)
TABLE 49. Global Phase III Market Size, by Country, 2017-2032 (USD Million)
TABLE 50. Global Preclinical Market Size, by Region, 2017-2032 (USD Million)
TABLE 51. Global Preclinical Market Size, by Group, 2017-2032 (USD Million)
TABLE 52. Global Preclinical Market Size, by Country, 2017-2032 (USD Million)
TABLE 53. Global GalNAc Delivery Technology Market Size, by Mechanism Of Action, 2017-2032 (USD Million)
TABLE 54. Global Antisense Oligonucleotides Market Size, by Region, 2017-2032 (USD Million)
TABLE 55. Global Antisense Oligonucleotides Market Size, by Group, 2017-2032 (USD Million)
TABLE 56. Global Antisense Oligonucleotides Market Size, by Country, 2017-2032 (USD Million)
TABLE 57. Global Morpholino Market Size, by Region, 2017-2032 (USD Million)
TABLE 58. Global Morpholino Market Size, by Group, 2017-2032 (USD Million)
TABLE 59. Global Morpholino Market Size, by Country, 2017-2032 (USD Million)
TABLE 60. Global Phosphorothioate Market Size, by Region, 2017-2032 (USD Million)
TABLE 61. Global Phosphorothioate Market Size, by Group, 2017-2032 (USD Million)
TABLE 62. Global Phosphorothioate Market Size, by Country, 2017-2032 (USD Million)
TABLE 63. Global Gene Editing Market Size, by Region, 2017-2032 (USD Million)
TABLE 64. Global Gene Editing Market Size, by Group, 2017-2032 (USD Million)
TABLE 65. Global Gene Editing Market Size, by Country, 2017-2032 (USD Million)
TABLE 66. Global Crispr Cas9 Market Size, by Region, 2017-2032 (USD Million)
TABLE 67. Global Crispr Cas9 Market Size, by Group, 2017-2032 (USD Million)
TABLE 68. Global Crispr Cas9 Market Size, by Country, 2017-2032 (USD Million)
TABLE 69. Global Talen Market Size, by Region, 2017-2032 (USD Million)
TABLE 70. Global Talen Market Size, by Group, 2017-2032 (USD Million)
TABLE 71. Global Talen Market Size, by Country, 2017-2032 (USD Million)
TABLE 72. Global Mrna Therapies Market Size, by Region, 2017-2032 (USD Million)
TABLE 73. Global Mrna Therapies Market Size, by Group, 2017-2032 (USD Million)
TABLE 74. Global Mrna Therapies Market Size, by Country, 2017-2032 (USD Million)
TABLE 75. Global Therapeutic Mrna Market Size, by Region, 2017-2032 (USD Million)
TABLE 76. Global Therapeutic Mrna Market Size, by Group, 2017-2032 (USD Million)
TABLE 77. Global Therapeutic Mrna Market Size, by Country, 2017-2032 (USD Million)
TABLE 78. Global Vaccine Mrna Market Size, by Region, 2017-2032 (USD Million)
TABLE 79. Global Vaccine Mrna Market Size, by Group, 2017-2032 (USD Million)
TABLE 80. Global Vaccine Mrna Market Size, by Country, 2017-2032 (USD Million)
TABLE 81. Global Rna Interference Market Size, by Region, 2017-2032 (USD Million)
TABLE 82. Global Rna Interference Market Size, by Group, 2017-2032 (USD Million)
TABLE 83. Global Rna Interference Market Size, by Country, 2017-2032 (USD Million)
TABLE 84. Global ShRNA Market Size, by Region, 2017-2032 (USD Million)
TABLE 85. Global ShRNA Market Size, by Group, 2017-2032 (USD Million)
TABLE 86. Global ShRNA Market Size, by Country, 2017-2032 (USD Million)
TABLE 87. Global SiRNA Market Size, by Region, 2017-2032 (USD Million)
TABLE 88. Global SiRNA Market Size, by Group, 2017-2032 (USD Million)
TABLE 89. Global SiRNA Market Size, by Country, 2017-2032 (USD Million)
TABLE 90. Global GalNAc Delivery Technology Market Size, by End User, 2017-2032 (USD Million)
TABLE 91. Global Academic Institutions Market Size, by Region, 2017-2032 (USD Million)
TABLE 92. Global Academic Institutions Market Size, by Group, 2017-2032 (USD Million)
TABLE 93. Global Academic Institutions Market Size, by Country, 2017-2032 (USD Million)
TABLE 94. Global Biotechnology Firms Market Size, by Region, 2017-2032 (USD Million)
TABLE 95. Global Biotechnology Firms Market Size, by Group, 2017-2032 (USD Million)
TABLE 96. Global Biotechnology Firms Market Size, by Country, 2017-2032 (USD Million)
TABLE 97. Global Contract Research Organizations Market Size, by Region, 2017-2032 (USD Million)
TABLE 98. Global Contract Research Organizations Market Size, by Group, 2017-2032 (USD Million)
TABLE 99. Global Contract Research Organizations Market Size, by Country, 2017-2032 (USD Million)
TABLE 100. Global Pharmaceutical Companies Market Size, by Region, 2017-2032 (USD Million)
TABLE 101. Global Pharmaceutical Companies Market Size, by Group, 2017-2032 (USD Million)
TABLE 102. Global Pharmaceutical Companies Market Size, by Country, 2017-2032 (USD Million)
TABLE 103. Global GalNAc Delivery Technology Market Size, by Region, 2017-2032 (USD Million)
TABLE 104. Asia-Pacific GalNAc Delivery Technology Market Size, by Region, 2017-2032 (USD Million)
TABLE 105. Asia-Pacific GalNAc Delivery Technology Market Size, by Therapeutic Area, 2017-2032 (USD Million)
TABLE 106. Asia-Pacific GalNAc Delivery Technology Market Size, by Cardiovascular Diseases, 2017-2032 (USD Million)
TABLE 107. Asia-Pacific GalNAc Delivery Technology Market Size, by Liver Diseases, 2017-2032 (USD Million)
TABLE 108. Asia-Pacific GalNAc Delivery Technology Market Size, by Metabolic Disorders, 2017-2032 (USD Million)
TABLE 109. Asia-Pacific GalNAc Delivery Technology Market Size, by Clinical Stage, 2017-2032 (USD Million)
TABLE 110. Asia-Pacific GalNAc Delivery Technology Market Size, by Phase I/II, 2017-2032 (USD Million)
TABLE 111. Asia-Pacific GalNAc Delivery Technology Market Size, by Mechanism Of Action, 2017-2032 (USD Million)
TABLE 112. Asia-Pacific GalNAc Delivery Technology Market Size, by Antisense Oligonucleotides, 2017-2032 (USD Million)
TABLE 113. Asia-Pacific GalNAc Delivery Technology Market Size, by Gene Editing, 2017-2032 (USD Million)
TABLE 114. Asia-Pacific GalNAc Delivery Technology Market Size, by Mrna Therapies, 2017-2032 (USD Million)
TABLE 115. Asia-Pacific GalNAc Delivery Technology Market Size, by Rna Interference, 2017-2032 (USD Million)
TABLE 116. Asia-Pacific GalNAc Delivery Technology Market Size, by End User, 2017-2032 (USD Million)
TABLE 117. North America GalNAc Delivery Technology Market Size, by Region, 2017-2032 (USD Million)
TABLE 118. North America GalNAc Delivery Technology Market Size, by Therapeutic Area, 2017-2032 (USD Million)
TABLE 119. North America GalNAc Delivery Technology Market Size, by Cardiovascular Diseases, 2017-2032 (USD Million)
TABLE 120. North America GalNAc Delivery Technology Market Size, by Liver Diseases, 2017-2032 (USD Million)
TABLE 121. North America GalNAc Delivery Technology Market Size, by Metabolic Disorders, 2017-2032 (USD Million)
TABLE 122. North America GalNAc Delivery Technology Market Size, by Clinical Stage, 2017-2032 (USD Million)
TABLE 123. North America GalNAc Delivery Technology Market Size, by Phase I/II, 2017-2032 (USD Million)
TABLE 124. North America GalNAc Delivery Technology Market Size, by Mechanism Of Action, 2017-2032 (USD Million)
TABLE 125. North America GalNAc Delivery Technology Market Size, by Antisense Oligonucleotides, 2017-2032 (USD Million)
TABLE 126. North America GalNAc Delivery Technology Market Size, by Gene Editing, 2017-2032 (USD Million)
TABLE 127. North America GalNAc Delivery Technology Market Size, by Mrna Therapies, 2017-2032 (USD Million)
TABLE 128. North America GalNAc Delivery Technology Market Size, by Rna Interference, 2017-2032 (USD Million)
TABLE 129. North America GalNAc Delivery Technology Market Size, by End User, 2017-2032 (USD Million)
TABLE 130. Latin America GalNAc Delivery Technology Market Size, by Region, 2017-2032 (USD Million)
TABLE 131. Latin America GalNAc Delivery Technology Market Size, by Therapeutic Area, 2017-2032 (USD Million)
TABLE 132. Latin America GalNAc Delivery Technology Market Size, by Cardiovascular Diseases, 2017-2032 (USD Million)
TABLE 133. Latin America GalNAc Delivery Technology Market Size, by Liver Diseases, 2017-2032 (USD Million)
TABLE 134. Latin America GalNAc Delivery Technology Market Size, by Metabolic Disorders, 2017-2032 (USD Million)
TABLE 135. Latin America GalNAc Delivery Technology Market Size, by Clinical Stage, 2017-2032 (USD Million)
TABLE 136. Latin America GalNAc Delivery Technology Market Size, by Phase I/II, 2017-2032 (USD Million)
TABLE 137. Latin America GalNAc Delivery Technology Market Size, by Mechanism Of Action, 2017-2032 (USD Million)
TABLE 138. Latin America GalNAc Delivery Technology Market Size, by Antisense Oligonucleotides, 2017-2032 (USD Million)
TABLE 139. Latin America GalNAc Delivery Technology Market Size, by Gene Editing, 2017-2032 (USD Million)
TABLE 140. Latin America GalNAc Delivery Technology Market Size, by Mrna Therapies, 2017-2032 (USD Million)
TABLE 141. Latin America GalNAc Delivery Technology Market Size, by Rna Interference, 2017-2032 (USD Million)
TABLE 142. Latin America GalNAc Delivery Technology Market Size, by End User, 2017-2032 (USD Million)
TABLE 143. Europe GalNAc Delivery Technology Market Size, by Region, 2017-2032 (USD Million)
TABLE 144. Europe GalNAc Delivery Technology Market Size, by Therapeutic Area, 2017-2032 (USD Million)
TABLE 145. Europe GalNAc Delivery Technology Market Size, by Cardiovascular Diseases, 2017-2032 (USD Million)
TABLE 146. Europe GalNAc Delivery Technology Market Size, by Liver Diseases, 2017-2032 (USD Million)
TABLE 147. Europe GalNAc Delivery Technology Market Size, by Metabolic Disorders, 2017-2032 (USD Million)
TABLE 148. Europe GalNAc Delivery Technology Market Size, by Clinical Stage, 2017-2032 (USD Million)
TABLE 149. Europe GalNAc Delivery Technology Market Size, by Phase I/II, 2017-2032 (USD Million)
TABLE 150. Europe GalNAc Delivery Technology Market Size, by Mechanism Of Action, 2017-2032 (USD Million)
TABLE 151. Europe GalNAc Delivery Technology Market Size, by Antisense Oligonucleotides, 2017-2032 (USD Million)
TABLE 152. Europe GalNAc Delivery Technology Market Size, by Gene Editing, 2017-2032 (USD Million)
TABLE 153. Europe GalNAc Delivery Technology Market Size, by Mrna Therapies, 2017-2032 (USD Million)
TABLE 154. Europe GalNAc Delivery Technology Market Size, by Rna Interference, 2017-2032 (USD Million)
TABLE 155. Europe GalNAc Delivery Technology Market Size, by End User, 2017-2032 (USD Million)
TABLE 156. Middle East GalNAc Delivery Technology Market Size, by Region, 2017-2032 (USD Million)
TABLE 157. Middle East GalNAc Delivery Technology Market Size, by Therapeutic Area, 2017-2032 (USD Million)
TABLE 158. Middle East GalNAc Delivery Technology Market Size, by Cardiovascular Diseases, 2017-2032 (USD Million)
TABLE 159. Middle East GalNAc Delivery Technology Market Size, by Liver Diseases, 2017-2032 (USD Million)
TABLE 160. Middle East GalNAc Delivery Technology Market Size, by Metabolic Disorders, 2017-2032 (USD Million)
TABLE 161. Middle East GalNAc Delivery Technology Market Size, by Clinical Stage, 2017-2032 (USD Million)
TABLE 162. Middle East GalNAc Delivery Technology Market Size, by Phase I/II, 2017-2032 (USD Million)
TABLE 163. Middle East GalNAc Delivery Technology Market Size, by Mechanism Of Action, 2017-2032 (USD Million)
TABLE 164. Middle East GalNAc Delivery Technology Market Size, by Antisense Oligonucleotides, 2017-2032 (USD Million)
TABLE 165. Middle East GalNAc Delivery Technology Market Size, by Gene Editing, 2017-2032 (USD Million)
TABLE 166. Middle East GalNAc Delivery Technology Market Size, by Mrna Therapies, 2017-2032 (USD Million)
TABLE 167. Middle East GalNAc Delivery Technology Market Size, by Rna Interference, 2017-2032 (USD Million)
TABLE 168. Middle East GalNAc Delivery Technology Market Size, by End User, 2017-2032 (USD Million)
TABLE 169. Africa GalNAc Delivery Technology Market Size, by Region, 2017-2032 (USD Million)
TABLE 170. Africa GalNAc Delivery Technology Market Size, by Therapeutic Area, 2017-2032 (USD Million)
TABLE 171. Africa GalNAc Delivery Technology Market Size, by Cardiovascular Diseases, 2017-2032 (USD Million)
TABLE 172. Africa GalNAc Delivery Technology Market Size, by Liver Diseases, 2017-2032 (USD Million)
TABLE 173. Africa GalNAc Delivery Technology Market Size, by Metabolic Disorders, 2017-2032 (USD Million)
TABLE 174. Africa GalNAc Delivery Technology Market Size, by Clinical Stage, 2017-2032 (USD Million)
TABLE 175. Africa GalNAc Delivery Technology Market Size, by Phase I/II, 2017-2032 (USD Million)
TABLE 176. Africa GalNAc Delivery Technology Market Size, by Mechanism Of Action, 2017-2032 (USD Million)
TABLE 177. Africa GalNAc Delivery Technology Market Size, by Antisense Oligonucleotides, 2017-2032 (USD Million)
TABLE 178. Africa GalNAc Delivery Technology Market Size, by Gene Editing, 2017-2032 (USD Million)
TABLE 179. Africa GalNAc Delivery Technology Market Size, by Mrna Therapies, 2017-2032 (USD Million)
TABLE 180. Africa GalNAc Delivery Technology Market Size, by Rna Interference, 2017-2032 (USD Million)
TABLE 181. Africa GalNAc Delivery Technology Market Size, by End User, 2017-2032 (USD Million)
TABLE 182. Global GalNAc Delivery Technology Market Size, by Group, 2017-2032 (USD Million)
TABLE 183. ASEAN GalNAc Delivery Technology Market Size, by Group, 2017-2032 (USD Million)
TABLE 184. ASEAN GalNAc Delivery Technology Market Size, by Therapeutic Area, 2017-2032 (USD Million)
TABLE 185. ASEAN GalNAc Delivery Technology Market Size, by Cardiovascular Diseases, 2017-2032 (USD Million)
TABLE 186. ASEAN GalNAc Delivery Technology Market Size, by Liver Diseases, 2017-2032 (USD Million)
TABLE 187. ASEAN GalNAc Delivery Technology Market Size, by Metabolic Disorders, 2017-2032 (USD Million)
TABLE 188. ASEAN GalNAc Delivery Technology Market Size, by Clinical Stage, 2017-2032 (USD Million)
TABLE 189. ASEAN GalNAc Delivery Technology Market Size, by Phase I/II, 2017-2032 (USD Million)
TABLE 190. ASEAN GalNAc Delivery Technology Market Size, by Mechanism Of Action, 2017-2032 (USD Million)
TABLE 191. ASEAN GalNAc Delivery Technology Market Size, by Antisense Oligonucleotides, 2017-2032 (USD Million)
TABLE 192. ASEAN GalNAc Delivery Technology Market Size, by Gene Editing, 2017-2032 (USD Million)
TABLE 193. ASEAN GalNAc Delivery Technology Market Size, by Mrna Therapies, 2017-2032 (USD Million)
TABLE 194. ASEAN GalNAc Delivery Technology Market Size, by Rna Interference, 2017-2032 (USD Million)
TABLE 195. ASEAN GalNAc Delivery Technology Market Size, by End User, 2017-2032 (USD Million)
TABLE 196. GCC GalNAc Delivery Technology Market Size, by Group, 2017-2032 (USD Million)
TABLE 197. GCC GalNAc Delivery Technology Market Size, by Therapeutic Area, 2017-2032 (USD Million)
TABLE 198. GCC GalNAc Delivery Technology Market Size, by Cardiovascular Diseases, 2017-2032 (USD Million)
TABLE 199. GCC GalNAc Delivery Technology Market Size, by Liver Diseases, 2017-2032 (USD Million)
TABLE 200. GCC GalNAc Delivery Technology Market Size, by Metabolic Disorders, 2017-2032 (USD Million)
TABLE 201. GCC GalNAc Delivery Technology Market Size, by Clinical Stage, 2017-2032 (USD Million)
TABLE 202. GCC GalNAc Delivery Technology Market Size, by Phase I/II, 2017-2032 (USD Million)
TABLE 203. GCC GalNAc Delivery Technology Market Size, by Mechanism Of Action, 2017-2032 (USD Million)
TABLE 204. GCC GalNAc Delivery Technology Market Size, by Antisense Oligonucleotides, 2017-2032 (USD Million)
TABLE 205. GCC GalNAc Delivery Technology Market Size, by Gene Editing, 2017-2032 (USD Million)
TABLE 206. GCC GalNAc Delivery Technology Market Size, by Mrna Therapies, 2017-2032 (USD Million)
TABLE 207. GCC GalNAc Delivery Technology Market Size, by Rna Interference, 2017-2032 (USD Million)
TABLE 208. GCC GalNAc Delivery Technology Market Size, by End User, 2017-2032 (USD Million)
TABLE 209. European Union GalNAc Delivery Technology Market Size, by Group, 2017-2032 (USD Million)
TABLE 210. European Union GalNAc Delivery Technology Market Size, by Therapeutic Area, 2017-2032 (USD Million)
TABLE 211. European Union GalNAc Delivery Technology Market Size, by Cardiovascular Diseases, 2017-2032 (USD Million)
TABLE 212. European Union GalNAc Delivery Technology Market Size, by Liver Diseases, 2017-2032 (USD Million)
TABLE 213. European Union GalNAc Delivery Technology Market Size, by Metabolic Disorders, 2017-2032 (USD Million)
TABLE 214. European Union GalNAc Delivery Technology Market Size, by Clinical Stage, 2017-2032 (USD Million)
TABLE 215. European Union GalNAc Delivery Technology Market Size, by Phase I/II, 2017-2032 (USD Million)
TABLE 216. European Union GalNAc Delivery Technology Market Size, by Mechanism Of Action, 2017-2032 (USD Million)
TABLE 217. European Union GalNAc Delivery Technology Market Size, by Antisense Oligonucleotides, 2017-2032 (USD Million)
TABLE 218. European Union GalNAc Delivery Technology Market Size, by Gene Editing, 2017-2032 (USD Million)
TABLE 219. European Union GalNAc Delivery Technology Market Size, by Mrna Therapies, 2017-2032 (USD Million)
TABLE 220. European Union GalNAc Delivery Technology Market Size, by Rna Interference, 2017-2032 (USD Million)
TABLE 221. European Union GalNAc Delivery Technology Market Size, by End User, 2017-2032 (USD Million)
TABLE 222. BRICS GalNAc Delivery Technology Market Size, by Group, 2017-2032 (USD Million)
TABLE 223. BRICS GalNAc Delivery Technology Market Size, by Therapeutic Area, 2017-2032 (USD Million)
TABLE 224. BRICS GalNAc Delivery Technology Market Size, by Cardiovascular Diseases, 2017-2032 (USD Million)
TABLE 225. BRICS GalNAc Delivery Technology Market Size, by Liver Diseases, 2017-2032 (USD Million)
TABLE 226. BRICS GalNAc Delivery Technology Market Size, by Metabolic Disorders, 2017-2032 (USD Million)
TABLE 227. BRICS GalNAc Delivery Technology Market Size, by Clinical Stage, 2017-2032 (USD Million)
TABLE 228. BRICS GalNAc Delivery Technology Market Size, by Phase I/II, 2017-2032 (USD Million)
TABLE 229. BRICS GalNAc Delivery Technology Market Size, by Mechanism Of Action, 2017-2032 (USD Million)
TABLE 230. BRICS GalNAc Delivery Technology Market Size, by Antisense Oligonucleotides, 2017-2032 (USD Million)
TABLE 231. BRICS GalNAc Delivery Technology Market Size, by Gene Editing, 2017-2032 (USD Million)
TABLE 232. BRICS GalNAc Delivery Technology Market Size, by Mrna Therapies, 2017-2032 (USD Million)
TABLE 233. BRICS GalNAc Delivery Technology Market Size, by Rna Interference, 2017-2032 (USD Million)
TABLE 234. BRICS GalNAc Delivery Technology Market Size, by End User, 2017-2032 (USD Million)
TABLE 235. G7 GalNAc Delivery Technology Market Size, by Group, 2017-2032 (USD Million)
TABLE 236. G7 GalNAc Delivery Technology Market Size, by Therapeutic Area, 2017-2032 (USD Million)
TABLE 237. G7 GalNAc Delivery Technology Market Size, by Cardiovascular Diseases, 2017-2032 (USD Million)
TABLE 238. G7 GalNAc Delivery Technology Market Size, by Liver Diseases, 2017-2032 (USD Million)
TABLE 239. G7 GalNAc Delivery Technology Market Size, by Metabolic Disorders, 2017-2032 (USD Million)
TABLE 240. G7 GalNAc Delivery Technology Market Size, by Clinical Stage, 2017-2032 (USD Million)
TABLE 241. G7 GalNAc Delivery Technology Market Size, by Phase I/II, 2017-2032 (USD Million)
TABLE 242. G7 GalNAc Delivery Technology Market Size, by Mechanism Of Action, 2017-2032 (USD Million)
TABLE 243. G7 GalNAc Delivery Technology Market Size, by Antisense Oligonucleotides, 2017-2032 (USD Million)
TABLE 244. G7 GalNAc Delivery Technology Market Size, by Gene Editing, 2017-2032 (USD Million)
TABLE 245. G7 GalNAc Delivery Technology Market Size, by Mrna Therapies, 2017-2032 (USD Million)
TABLE 246. G7 GalNAc Delivery Technology Market Size, by Rna Interference, 2017-2032 (USD Million)
TABLE 247. G7 GalNAc Delivery Technology Market Size, by End User, 2017-2032 (USD Million)
TABLE 248. NATO GalNAc Delivery Technology Market Size, by Group, 2017-2032 (USD Million)
TABLE 249. NATO GalNAc Delivery Technology Market Size, by Therapeutic Area, 2017-2032 (USD Million)
TABLE 250. NATO GalNAc Delivery Technology Market Size, by Cardiovascular Diseases, 2017-2032 (USD Million)
TABLE 251. NATO GalNAc Delivery Technology Market Size, by Liver Diseases, 2017-2032 (USD Million)
TABLE 252. NATO GalNAc Delivery Technology Market Size, by Metabolic Disorders, 2017-2032 (USD Million)
TABLE 253. NATO GalNAc Delivery Technology Market Size, by Clinical Stage, 2017-2032 (USD Million)
TABLE 254. NATO GalNAc Delivery Technology Market Size, by Phase I/II, 2017-2032 (USD Million)
TABLE 255. NATO GalNAc Delivery Technology Market Size, by Mechanism Of Action, 2017-2032 (USD Million)
TABLE 256. NATO GalNAc Delivery Technology Market Size, by Antisense Oligonucleotides, 2017-2032 (USD Million)
TABLE 257. NATO GalNAc Delivery Technology Market Size, by Gene Editing, 2017-2032 (USD Million)
TABLE 258. NATO GalNAc Delivery Technology Market Size, by Mrna Therapies, 2017-2032 (USD Million)
TABLE 259. NATO GalNAc Delivery Technology Market Size, by Rna Interference, 2017-2032 (USD Million)
TABLE 260. NATO GalNAc Delivery Technology Market Size, by End User, 2017-2032 (USD Million)
TABLE 261. Global GalNAc Delivery Technology Market Size, by Country, 2017-2032 (USD Million)
TABLE 262. United States GalNAc Delivery Technology Market Size, 2017-2032 (USD Million)
TABLE 263. United States GalNAc Delivery Technology Market Size, by Therapeutic Area, 2017-2032 (USD Million)
TABLE 264. United States GalNAc Delivery Technology Market Size, by Cardiovascular Diseases, 2017-2032 (USD Million)
TABLE 265. United States GalNAc Delivery Technology Market Size, by Liver Diseases, 2017-2032 (USD Million)
TABLE 266. United States GalNAc Delivery Technology Market Size, by Metabolic Disorders, 2017-2032 (USD Million)
TABLE 267. United States GalNAc Delivery Technology Market Size, by Clinical Stage, 2017-2032 (USD Million)
TABLE 268. United States GalNAc Delivery Technology Market Size, by Phase I/II, 2017-2032 (USD Million)
TABLE 269. United States GalNAc Delivery Technology Market Size, by Mechanism Of Action, 2017-2032 (USD Million)
TABLE 270. United States GalNAc Delivery Technology Market Size, by Antisense Oligonucleotides, 2017-2032 (USD Million)
TABLE 271. United States GalNAc Delivery Technology Market Size, by Gene Editing, 2017-2032 (USD Million)
TABLE 272. United States GalNAc Delivery Technology Market Size, by Mrna Therapies, 2017-2032 (USD Million)
TABLE 273. United States GalNAc Delivery Technology Market Size, by Rna Interference, 2017-2032 (USD Million)
TABLE 274. United States GalNAc Delivery Technology Market Size, by End User, 2017-2032 (USD Million)
TABLE 275. Canada GalNAc Delivery Technology Market Size, 2017-2032 (USD Million)
TABLE 276. Canada GalNAc Delivery Technology Market Size, by Therapeutic Area, 2017-2032 (USD Million)
TABLE 277. Canada GalNAc Delivery Technology Market Size, by Cardiovascular Diseases, 2017-2032 (USD Million)
TABLE 278. Canada GalNAc Delivery Technology Market Size, by Liver Diseases, 2017-2032 (USD Million)
TABLE 279. Canada GalNAc Delivery Technology Market Size, by Metabolic Disorders, 2017-2032 (USD Million)
TABLE 280. Canada GalNAc Delivery Technology Market Size, by Clinical Stage, 2017-2032 (USD Million)
TABLE 281. Canada GalNAc Delivery Technology Market Size, by Phase I/II, 2017-2032 (USD Million)
TABLE 282. Canada GalNAc Delivery Technology Market Size, by Mechanism Of Action, 2017-2032 (USD Million)
TABLE 283. Canada GalNAc Delivery Technology Market Size, by Antisense Oligonucleotides, 2017-2032 (USD Million)
TABLE 284. Canada GalNAc Delivery Technology Market Size, by Gene Editing, 2017-2032 (USD Million)
TABLE 285. Canada GalNAc Delivery Technology Market Size, by Mrna Therapies, 2017-2032 (USD Million)
TABLE 286. Canada GalNAc Delivery Technology Market Size, by Rna Interference, 2017-2032 (USD Million)
TABLE 287. Canada GalNAc Delivery Technology Market Size, by End User, 2017-2032 (USD Million)
TABLE 288. Mexico GalNAc Delivery Technology Market Size, 2017-2032 (USD Million)
TABLE 289. Mexico GalNAc Delivery Technology Market Size, by Therapeutic Area, 2017-2032 (USD Million)
TABLE 290. Mexico GalNAc Delivery Technology Market Size, by Cardiovascular Diseases, 2017-2032 (USD Million)
TABLE 291. Mexico GalNAc Delivery Technology Market Size, by Liver Diseases, 2017-2032 (USD Million)
TABLE 292. Mexico GalNAc Delivery Technology Market Size, by Metabolic Disorders, 2017-2032 (USD Million)
TABLE 293. Mexico GalNAc Delivery Technology Market Size, by Clinical Stage, 2017-2032 (USD Million)
TABLE 294. Mexico GalNAc Delivery Technology Market Size, by Phase I/II, 2017-2032 (USD Million)
TABLE 295. Mexico GalNAc Delivery Technology Market Size, by Mechanism Of Action, 2017-2032 (USD Million)
TABLE 296. Mexico GalNAc Delivery Technology Market Size, by Antisense Oligonucleotides, 2017-2032 (USD Million)
TABLE 297. Mexico GalNAc Delivery Technology Market Size, by Gene Editing, 2017-2032 (USD Million)
TABLE 298. Mexico GalNAc Delivery Technology Market Size, by Mrna Therapies, 2017-2032 (USD Million)
TABLE 299. Mexico GalNAc Delivery Technology Market Size, by Rna Interference, 2017-2032 (USD Million)
TABLE 300. Mexico GalNAc Delivery Technology Market Size, by End User, 2017-2032 (USD Million)
TABLE 301. Brazil GalNAc Delivery Technology Market Size, 2017-2032 (USD Million)
TABLE 302. Brazil GalNAc Delivery Technology Market Size, by Therapeutic Area, 2017-2032 (USD Million)
TABLE 303. Brazil GalNAc Delivery Technology Market Size, by Cardiovascular Diseases, 2017-2032 (USD Million)
TABLE 304. Brazil GalNAc Delivery Technology Market Size, by Liver Diseases, 2017-2032 (USD Million)
TABLE 305. Brazil GalNAc Delivery Technology Market Size, by Metabolic Disorders, 2017-2032 (USD Million)
TABLE 306. Brazil GalNAc Delivery Technology Market Size, by Clinical Stage, 2017-2032 (USD Million)
TABLE 307. Brazil GalNAc Delivery Technology Market Size, by Phase I/II, 2017-2032 (USD Million)
TABLE 308. Brazil GalNAc Delivery Technology Market Size, by Mechanism Of Action, 2017-2032 (USD Million)
TABLE 309. Brazil GalNAc Delivery Technology Market Size, by Antisense Oligonucleotides, 2017-2032 (USD Million)
TABLE 310. Brazil GalNAc Delivery Technology Market Size, by Gene Editing, 2017-2032 (USD Million)
TABLE 311. Brazil GalNAc Delivery Technology Market Size, by Mrna Therapies, 2017-2032 (USD Million)
TABLE 312. Brazil GalNAc Delivery Technology Market Size, by Rna Interference, 2017-2032 (USD Million)
TABLE 313. Brazil GalNAc Delivery Technology Market Size, by End User, 2017-2032 (USD Million)
TABLE 314. United Kingdom GalNAc Delivery Technology Market Size, 2017-2032 (USD Million)
TABLE 315. United Kingdom GalNAc Delivery Technology Market Size, by Therapeutic Area, 2017-2032 (USD Million)
TABLE 316. United Kingdom GalNAc Delivery Technology Market Size, by Cardiovascular Diseases, 2017-2032 (USD Million)
TABLE 317. United Kingdom GalNAc Delivery Technology Market Size, by Liver Diseases, 2017-2032 (USD Million)
TABLE 318. United Kingdom GalNAc Delivery Technology Market Size, by Metabolic Disorders, 2017-2032 (USD Million)
TABLE 319. United Kingdom GalNAc Delivery Technology Market Size, by Clinical Stage, 2017-2032 (USD Million)
TABLE 320. United Kingdom GalNAc Delivery Technology Market Size, by Phase I/II, 2017-2032 (USD Million)
TABLE 321. United Kingdom GalNAc Delivery Technology Market Size, by Mechanism Of Action, 2017-2032 (USD Million)
TABLE 322. United Kingdom GalNAc Delivery Technology Market Size, by Antisense Oligonucleotides, 2017-2032 (USD Million)
TABLE 323. United Kingdom GalNAc Delivery Technology Market Size, by Gene Editing, 2017-2032 (USD Million)
TABLE 324. United Kingdom GalNAc Delivery Technology Market Size, by Mrna Therapies, 2017-2032 (USD Million)
TABLE 325. United Kingdom GalNAc Delivery Technology Market Size, by Rna Interference, 2017-2032 (USD Million)
TABLE 326. United Kingdom GalNAc Delivery Technology Market Size, by End User, 2017-2032 (USD Million)
TABLE 327. Germany GalNAc Delivery Technology Market Size, 2017-2032 (USD Million)
TABLE 328. Germany GalNAc Delivery Technology Market Size, by Therapeutic Area, 2017-2032 (USD Million)
TABLE 329. Germany GalNAc Delivery Technology Market Size, by Cardiovascular Diseases, 2017-2032 (USD Million)
TABLE 330. Germany GalNAc Delivery Technology Market Size, by Liver Diseases, 2017-2032 (USD Million)
TABLE 331. Germany GalNAc Delivery Technology Market Size, by Metabolic Disorders, 2017-2032 (USD Million)
TABLE 332. Germany GalNAc Delivery Technology Market Size, by Clinical Stage, 2017-2032 (USD Million)
TABLE 333. Germany GalNAc Delivery Technology Market Size, by Phase I/II, 2017-2032 (USD Million)
TABLE 334. Germany GalNAc Delivery Technology Market Size, by Mechanism Of Action, 2017-2032 (USD Million)
TABLE 335. Germany GalNAc Delivery Technology Market Size, by Antisense Oligonucleotides, 2017-2032 (USD Million)
TABLE 336. Germany GalNAc Delivery Technology Market Size, by Gene Editing, 2017-2032 (USD Million)
TABLE 337. Germany GalNAc Delivery Technology Market Size, by Mrna Therapies, 2017-2032 (USD Million)
TABLE 338. Germany GalNAc Delivery T

Companies Mentioned

  • Akcea Therapeutics, Inc.
  • Alnylam Pharmaceuticals, Inc.
  • Arcturus Therapeutics Holdings Inc.
  • Arrowhead Pharmaceuticals, Inc.
  • AstraZeneca plc
  • Bayer AG
  • Beam Therapeutics Inc.
  • BioNTech SE
  • CRISPR Therapeutics AG
  • CureVac N.V.
  • Editas Medicine, Inc.
  • GlaxoSmithKline plc
  • Ionis Pharmaceuticals, Inc.
  • Moderna, Inc.
  • Novartis AG
  • Pfizer Inc.
  • Pfizer Inc.
  • Regeneron Pharmaceuticals, Inc.
  • Roche Holding AG
  • Sanofi S.A.
  • Sarepta Therapeutics, Inc.
  • Takeda Development Center Americas, Inc.
  • Takeda Pharmaceutical Company Limited

Related Topics

Related Reports

RNAi Drug Delivery Market - Global Strategic Business Report - Product Image

RNAi Drug Delivery Market - Global Strategic Business Report

  • Report
  • 294 Pages
  • Global
From
Advanced Dermatology Drug Delivery Devices Market - Global Forecast 2026-2032 - Product Image

Advanced Dermatology Drug Delivery Devices Market - Global Forecast 2026-2032

  • Report
  • 180 Pages
  • Global
From
Novel Drug Delivery Systems Market - Global Forecast 2026-2032 - Product Image

Novel Drug Delivery Systems Market - Global Forecast 2026-2032

  • Report
  • 187 Pages
  • Global
From
RNAi Drug Delivery - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031) - Product Image

RNAi Drug Delivery - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

  • Report
  • 180 Pages
  • Global
From
Drug Delivery Devices - Market Insights, Competitive Landscape, and Market Forecast - 2032 - Product Image

Drug Delivery Devices - Market Insights, Competitive Landscape, and Market Forecast - 2032

  • Report
  • 150 Pages
  • Global
From
Copyright © 2002-2026 Research and Markets. All Rights Reserved.